John P. Giraldo, Chief Accounting Officer of Spotify Technology S.A., filed a Form 4 on November 3, 2026, disclosing a disposition of ordinary shares on November 1, 2026, related to the vesting of restricted stock units.
David L. Finkelstein, CEO and Co-CIO of Annaly Capital Management, Inc., filed a Form 4 on November 3, 2026, disclosing the sale of 48,223 shares of common stock on November 2, 2026, under a pre-established Rule 10b5-1 trading plan.
Lucas E. Montarce, Executive Vice President and CFO of Eli Lilly & Co (NYSE:LLY), filed a Form 4 on November 3, 2026, disclosing the vesting of 1,610 restricted stock units and a related tax-withholding disposition of shares on November 1, 2026.
Michael A. Sherrick, EVP and Chief Financial Officer of Information Services Group Inc. (NASDAQ:III), filed a Form 4 on November 3, 2026, disclosing the vesting of 27,778 performance-based restricted stock units and a related tax-withholding share disposition on October 30, 2026.
Daniel Skovronsky, Executive Vice President and officer of Eli Lilly & Co (NYSE:LLY), filed a Form 4 on November 3, 2026, disclosing a gift of 119 shares of common stock on November 2, 2026.
Todd D. Lavieri, Vice Chairman of Information Services Group Inc. (NASDAQ:III), filed a Form 4 on November 3, 2026, disclosing the vesting of 39,683 performance-based restricted stock units and a related tax-withholding share disposition on October 30, 2026.
Thomas S. Kucinski, Executive Vice President and Chief HR Officer of Information Services Group Inc., filed a Form 4 on November 3, 2026, disclosing the vesting of performance-based restricted stock units and a related tax withholding disposition on October 30, 2026.
Roy Galvin, Executive Vice President and Chief Commercial Officer of Haemonetics Corporation, filed a Form 4 on November 3, 2026, disclosing a disposition of 146 shares of common stock on October 30, 2026, related to RSU vesting tax obligations.
tZERO Group, Inc. filed a Form 425 on November 3, 2026, disclosing social media posts it published regarding its proposed business combination with FG Imperii Acquisition Corp. (NASDAQ:FGII), a special purpose acquisition company focused on the North American financial services sector.
Qiming Corporate GP VI, Ltd. and affiliated Qiming entities filed a Form 4 with the SEC on November 3, 2026, disclosing sales of Alamar Biosciences, Inc. (NASDAQ:ALMR) common stock across multiple transactions on October 30, 2026 and November 2, 2026.